F-3 | ||||
F-4 | ||||
F-5 | ||||
F-6 | ||||
F-7 | ||||
F-8-F-35 |
December 31, 2023 |
December 31, 2022 |
|||||||
ASSETS |
||||||||
Current assets |
||||||||
Cash and cash equivalents (Note 20) |
$ | $ | ||||||
Prepaid expenses and deposits |
||||||||
Amounts receivable (Note 4) |
||||||||
Total current assets |
||||||||
Non-current assets |
||||||||
Prepaid expenses |
||||||||
Property and equipment, net (Note 5) |
||||||||
Right-of-use |
||||||||
Total assets |
$ | $ | ||||||
LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT) |
||||||||
Current liabilities |
||||||||
Accounts payable and accrued liabilities (Note 7) |
$ | $ | ||||||
Loans payable – current portion (Note 8) |
||||||||
Lease liability – current portion (Note 9) |
||||||||
Payable to Auritec (Note 10) |
— | |||||||
Convertible debt (Note 11) |
— | |||||||
Total current liabilities |
||||||||
Non-current liabilities |
||||||||
Loans payable (Note 8) |
— | |||||||
Lease liability (Note 9) |
— | |||||||
Convertible debt (Note 11) |
— | |||||||
Total liabilities |
||||||||
Shareholders’ equity (deficit) |
||||||||
Share capital, ; shares authorized; issued and outstanding: |
||||||||
Additional paid-in capital (Notes 12(b), 12(c) and 12(d)) |
||||||||
Deficit |
( |
) | ( |
) | ||||
Accumulated other comprehensive loss |
( |
) |
( |
) | ||||
Equity attributable to the owners of the Company |
||||||||
Non-controlling interest |
( |
) | ( |
) | ||||
Total shareholders’ equity (deficit) |
||||||||
Total liabilities and shareholders’ equity (deficit) |
$ | $ | ||||||
Year ended December 31, 2023 |
Year ended December 31, 2022 |
|||||||
Expenses |
||||||||
General and administrative (Note 13) |
$ | $ | ||||||
Research and development (Note 14) |
||||||||
Total expenses |
||||||||
Other income/(expenses) |
||||||||
Interest income |
||||||||
Interest expense (Note 19) |
( |
) | ( |
) | ||||
Loss on sale of equipment (Note 5) |
( |
) | ( |
) | ||||
Foreign exchange gain |
||||||||
Change in fair value of financial instruments (Note 11) |
( |
) | ( |
) | ||||
Total other income |
( |
) | ( |
) | ||||
Net loss before tax expense |
( |
) | ( |
) | ||||
Tax expense (Note 16) |
( |
) | — | |||||
Net loss for the year |
$ | ( |
) | $ | ( |
) | ||
Loss attributable to: |
||||||||
Owners of the Company |
$ | ( |
) | $ | ( |
) | ||
Non-controlling interest |
( |
) | ( |
) | ||||
( |
) | ( |
) | |||||
Foreign currency translation adjustment |
( |
) | ||||||
Comprehensive loss for the year |
$ | ( |
) | $ | ( |
) | ||
Loss per share – basic and diluted (Owners of the Company) |
$ | ( |
) | $ | ( |
) | ||
Weighted average shares outstanding – basic and diluted |
||||||||
Number of shares |
Amount |
Additional paid- in capital |
Deficit |
Accumulated other comprehensive income |
Non-controlling interest |
Total |
||||||||||||||||||||||
Balance, December 31, 2021 |
$ | $ | $ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ||||||||||||||||
Overnight marketed public offering, net of transaction costs (Note 12(b)(i)) |
— | — | — | |||||||||||||||||||||||||
Redemption of warrants (Notes 12(b)(ii) and 12(d)) |
( |
) | — | — | — | |||||||||||||||||||||||
Share-based payments (Note 12(c)) |
— | — | — | — | — | |||||||||||||||||||||||
Net loss for the year |
— | — | — | ( |
) | — | ( |
) | ( |
) | ||||||||||||||||||
Foreign Currency translation adjustment |
— | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance, December 31, 2022 |
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||
Non-brokered private placement, net of transaction costs(Note 12(b)(v)) |
— | — | — | — | ||||||||||||||||||||||||
Share-based payments (Note 12(c)) |
— | — | — | — | — | |||||||||||||||||||||||
Redemption of warrants (Notes 12(b)(iii) and 12(d)) |
( |
) | — | — | — | |||||||||||||||||||||||
Redemption of options (Notes 12(b)(iv) and 12(c)) |
( |
) | — | — | — | |||||||||||||||||||||||
Net loss for the year |
— | — | — | ( |
) | — | ( |
) | ( |
) | ||||||||||||||||||
Foreign currency translation adjustment |
— | — | — | — | — | |||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance, December 31, 2023 |
$ | $ | $ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year ended December 31, 2023 |
Year ended December 31, 2022 |
|||||||
CASH FLOWS FROM OPERATING ACTIVITIES |
||||||||
Net loss |
$ | ( |
) | $ | ( |
) | ||
Items not affecting cash |
||||||||
Accrued interest on convertible debt (Note 11) |
||||||||
Accrued interest on short term investments |
— | ( |
) | |||||
Depreciation (Note 5 and 6) |
||||||||
Interest – lease liability |
||||||||
Loss on sale of equipment |
||||||||
Share-based payments (Note 12(c)) |
||||||||
Change in fair value of financial instruments (Note 11) |
||||||||
Unrealized foreign exchange |
( |
) | ( |
) | ||||
Changes in operating assets and liabilities |
||||||||
Accounts payable and accrued liabilities |
||||||||
Auritec payable (Note 10) |
— | |||||||
Prepaid expenses |
( |
) | ( |
) | ||||
Amounts receivable |
( |
) | ||||||
Cash used in operating activities |
( |
) | ( |
) | ||||
CASH FLOWS FROM INVESTING ACTIVITIES |
||||||||
Acquisition of equipment |
( |
) | ( |
) | ||||
Proceeds from sale of equipment (Note 5) |
— | |||||||
Purchase of short term investments |
— | ( |
) | |||||
Proceeds from redemption of short-term investments |
— | |||||||
Cash provided by (used in) investing activities |
( |
) | ||||||
CASH FLOWS FROM FINANCING ACTIVITIES |
||||||||
Overnight marketed public offering (net of transaction costs) (Note 12(b)(i) and (v)) |
||||||||
Redemption of warrants (Note 12(d)) |
||||||||
Redemption of options (Note 12 (c)) |
— | |||||||
Repayment of loans (Note 8) |
( |
) | ( |
) | ||||
Lease payments (Note 9) |
( |
) | ( |
) | ||||
Cash provided by financing activities |
||||||||
Increase in cash and cash equivalents |
||||||||
Foreign exchange effect on cash and cash equivalents |
( |
) | ||||||
Cash and cash equivalents, beginning of year |
||||||||
Cash and cash equivalents, end of year |
$ |
$ |
||||||
1. |
NATURE OF BUSINESS AND GOING CONCERN |
1. |
NATURE OF BUSINESS AND GOING CONCERN (continued) |
2. |
BASIS OF PRESENTATION |
3. |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
3. |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) |
Company Entity |
Date of Incorporation |
Jurisdiction of Incorporation |
Effective Interest (Note 13(e)) |
|||||||
Eupraxia Holdings, Inc. |
% | |||||||||
Eupraxia Pharmaceuticals USA, LLC |
% | |||||||||
AMDM Holdings Inc. (2) |
% | |||||||||
Eupraxia Pharma, Inc. |
% | |||||||||
Eupraxia Pharmaceuticals Australia Pty Ltd. |
% (1) | |||||||||
Eupraxia Pharma USA Inc. |
% (1) |
(1) |
Wholly-owned subsidiary of Eupraxia Pharmaceuticals Inc. |
(2) |
Date of Control occurred on January 31, 2021 (see Note 13(e)). |
Computers | ||
Office furniture and equipment | ||
Leasehold improvements | ||
Lab equipment |
3. |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) |
3. |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) |
3. |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) |
3. |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) |
i. |
Level 1 – Unadjusted quoted prices in active markets for identical instruments. |
ii. |
Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the financial instrument, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability and inputs that are derived principally from or corroborated by observable market data by correlation or other means. |
iii. |
Inputs are unobservable and reflect the Company’s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available. |
3. |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) |
4. |
AMOUNTS RECEIVABLE |
December 31, |
December 31, |
|||||||
2023 |
2022 |
|||||||
Government grants (Note 14) |
$ | — | $ | |||||
GST/HST recoverable |
||||||||
Other refundable tax credits (1) |
||||||||
Total |
$ |
$ |
||||||
(1) | Other refundable tax credits are due to tax incentives for R&D costs incurred by Eupraxia Australia (Note 14 – Research and Development Expenses). |
5. |
PROPERTY AND EQUIPMENT |
Computers |
Office furniture and equipment |
Leasehold Improvements |
Lab Equipment |
Total |
||||||||||||||||
Cost |
||||||||||||||||||||
As at January 1, 2022 |
$ |
$ |
$ |
$ |
$ |
|||||||||||||||
Additions |
— |
|||||||||||||||||||
Disposals |
( |
) |
( |
) |
— |
— |
( |
) | ||||||||||||
Foreign currency adjustments |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||
As at December 31, 2022 |
||||||||||||||||||||
Additions |
— |
— |
||||||||||||||||||
Disposals |
( |
) |
— |
— |
( |
) |
( |
) | ||||||||||||
Foreign currency adjustments |
||||||||||||||||||||
As at December 31, 2023 |
||||||||||||||||||||
Accumulated Depreciation |
||||||||||||||||||||
As at January 1, 2022 |
||||||||||||||||||||
Depreciation |
||||||||||||||||||||
Disposals |
( |
) |
( |
) |
— |
— |
( |
) | ||||||||||||
Foreign currency adjustments |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||
As at December 31, 2022 |
||||||||||||||||||||
Depreciation |
||||||||||||||||||||
Disposals |
( |
) |
— |
— |
( |
) |
( |
) | ||||||||||||
Foreign currency adjustments |
||||||||||||||||||||
As at December 31, 2023 |
||||||||||||||||||||
Net Book Value |
||||||||||||||||||||
As at December 31, 2022 |
||||||||||||||||||||
As at December 31, 2023 |
$ |
$ |
$ |
$ |
$ |
|||||||||||||||
6. |
RIGHT-OF-USE |
December 31, 2023 |
December 31, 2022 |
|||||||
Balance, beginning |
$ |
$ |
||||||
Depreciation |
( |
) | ( |
) | ||||
Foreign Exchange |
( |
) | ||||||
Balance, ending |
$ |
$ |
||||||
7. |
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES |
December 31, 2023 |
December 31, 2022 |
|||||||
Research and development |
$ | $ | ||||||
General and administrative |
||||||||
Wages and payroll remittances |
||||||||
Employee bonus payable (1) |
||||||||
Taxes payable |
— | |||||||
Total |
$ |
$ |
||||||
(1) | Bonus relates to corporate bonuses for the years ended December 31, 2023 and 2022. |
8. |
LOANS PAYABLE |
December 31, 2023 |
December 31, 2022 |
|||||||
Balance, beginning |
$ |
$ |
||||||
Loan repayment |
( |
) | ( |
) | ||||
Foreign exchange adjustment |
( |
) | ||||||
Balance, ending |
$ |
$ |
||||||
Current portion |
$ |
$ |
||||||
Non-current portion |
$ |
— |
$ |
9. |
LEASE LIABILITY |
December 31, |
December 31, |
|||||||
2023 |
2022 |
|||||||
Lease Cost |
||||||||
Operating lease expense |
$ | $ | ||||||
Variable lease expense |
||||||||
Lease term and Discount Rate |
||||||||
Weighted average remaining lease term (years) |
||||||||
Weighted average discount rate |
% | % |
Year ending December 31: |
||||
2024 |
||||
Total undiscounted future minimum lease payments |
$ |
|||
Less: balance of unused tenant allowance |
||||
Less: imputed interest |
( |
) | ||
Present value of lease liabilities at December 31, 2023 |
$ |
|||
December 31, 2023 |
December 31, 2022 |
|||||||
Current portion |
$ | $ | ||||||
Non-current portion |
— | |||||||
$ |
$ |
|||||||
10. |
AURITEC LICENSE AGREEMENT |
Milestone Event |
Milestone Payment |
|||
Successful Completion of a Phase 2b Study |
||||
First OA Regulatory Approval |
||||
Second OA Regulatory Approval |
||||
Non-OA Indication Regulatory Approval |
||||
First calendar year in which aggregate Net Sales by Eupraxia USA, its affiliates and sublicenses exceed $500,000,000 |
||||
Maximum milestones payable |
$ |
|||
10. |
AURITEC LICENSE AGREEMENT (continued) |
Date of Execution |
Percentage of Non-Royalty Monetization Revenue |
|||
Prior to Successful Completion of a Phase 2b Study |
% | |||
After Successful Completion of a Phase 2b Study but prior to Successful Completion of a Phase 3 Study |
% | |||
After Successful Completion of a Phase 3 Study but prior to Regulatory Approval of a Product in the Eupraxia Field from FDA in the United States |
% | |||
After Regulatory Approval of a Product in the Eupraxia Field from FDA in the United States |
% |
11. |
CONVERTIBLE DEBT |
i. |
ii. |
11. |
CONVERTIBLE DEBT (continued) |
Balance – December 31, 2021 |
$ |
|||
Accrued interest |
||||
Interest paid |
( |
) | ||
Change in fair value |
||||
Foreign exchange |
( |
) | ||
Balance – December 31, 2022 |
$ |
|||
Accrued interest |
||||
Interest paid |
( |
) | ||
Change in fair value |
||||
Foreign exchange |
||||
Balance – December 31, 2023 |
$ |
|||
12. |
SHARE CAPITAL AND OTHER COMPONENTS OF EQUITY |
a) | Authorized |
• | An number of Common shares, with |
• | An number of Preferred shares, with |
b) | Issued |
i) | On April 20, 2022, the Company announced that it had closed an overnight marketed public offering (the “Offering”). Pursuant to the Offering, Eupraxia issued related to the value of the shares and $related to the value of the warrants). |
ii) | During the year ended December 31, 2022, paid-in capital to share capital. |
iii) | During the year ended December 31, 2023, paid-in capital to share capital. |
iv) | During the year ended December 31, 2023, paid-in capital to share capital. |
v) | On August 18, 2023, the Company closed a non-brokered private placement (the “Private Placement”). Pursuant to the Private Placement, the Company issued common shares as finder’s fees which were valued at $ |
12. |
SHARE CAPITAL AND OTHER COMPONENTS OF EQUITY (continued) |
c) |
Options |
Number of options |
Weighted average exercise price (CDN$) |
|||||||
Outstanding, December 31, 2021 |
$ | |||||||
Granted |
||||||||
Outstanding, December 31, 2022 |
||||||||
Exercised |
( |
) | ||||||
Cancelled |
( |
) | ||||||
Granted |
||||||||
Outstanding, December 31, 2023 |
$ |
|||||||
Grant Date |
Options Outstanding |
Options Exercisable |
Exercise Price (CDN$) |
Expiry Date |
Remaining Contractual Life (years) |
|||||||||||||||
$ | (3) |
|||||||||||||||||||
$ | (3) |
|||||||||||||||||||
$ | (3) |
|||||||||||||||||||
$ | ||||||||||||||||||||
$ | ||||||||||||||||||||
$ | ||||||||||||||||||||
$ | ||||||||||||||||||||
$ | ||||||||||||||||||||
$ | ||||||||||||||||||||
$ | ||||||||||||||||||||
$ | ||||||||||||||||||||
$ | ||||||||||||||||||||
$ |
||||||||||||||||||||
12. |
SHARE CAPITAL AND OTHER COMPONENTS OF EQUITY (continued) |
December 31, |
December 31, |
|||||||
Options granted during the year ended |
2023 |
2022 |
||||||
Expected dividend yield |
% | % | ||||||
Expected forfeiture rate |
% | % | ||||||
Weighted average annual volatility |
% | % | ||||||
Weighted average risk-free interest rate |
% | % | ||||||
Weighted average expected option life |
||||||||
Weighted average share price (CDN$) |
$ | $ | ||||||
Weighted average exercise price (CDN$) |
$ | $ | ||||||
Weighted average fair value of options granted (CDN$) |
$ | $ |
d) | Warrants |
Number of warrants |
Weighted average exercise price (CDN$) |
|||||||
Outstanding December 31, 2021 |
$ |
|||||||
Issued |
||||||||
Expired |
( |
) | ||||||
Exercised |
( |
) | ||||||
Outstanding December 31, 2022 |
$ |
|||||||
Exercised |
( |
) | ||||||
Outstanding December 31, 2023 |
$ |
|||||||
12. |
SHARE CAPITAL AND OTHER COMPONENTS OF EQUITY (continued) |
d) |
Warrants (continued) |
Expiry date |
Exercise price (CDN$) |
Remaining contractual life (years) |
Warrants outstanding and exercisable |
|||||||||
$ | N/A | |||||||||||
N/A | ||||||||||||
holder ceases to be a Director/ Officer or consultant (1) |
N/A | |||||||||||
$ |
||||||||||||
(1) |
Represents unit purchase to acquire |
e) | Class B Non-Voting shares |
13. |
GENERAL AND ADMINISTRATIVE EXPENSES |
December 31, |
December 31, |
|||||||
2023 |
2022 |
|||||||
Office expenses |
$ | $ | ||||||
Insurance |
||||||||
Travel |
||||||||
Professional fees |
||||||||
Public company costs |
||||||||
Salaries and benefits |
||||||||
Share based payments (Note 12(c)) |
||||||||
Total expenses during the period |
$ |
$ |
||||||
14. |
RESEARCH AND DEVELOPMENT EXPENSES |
December 31, 2023 |
December 31, 2022 |
|||||||
Preclinical |
$ | $ | ||||||
Clinical |
||||||||
Manufacturing & analytical |
||||||||
Regulatory |
||||||||
Consulting |
||||||||
Direct research and development |
||||||||
Pipeline development |
||||||||
Other research and development |
||||||||
Salaries and benefits |
||||||||
Share based payments (Note 12(c)) |
||||||||
License costs (Note 10) |
||||||||
Government grants (Note 15) |
( |
) | ( |
) | ||||
SR&ED and other R&D tax incentives |
( |
) | ( |
) | ||||
Total expenses during the period |
$ |
$ |
||||||
15. |
GOVERNMENT GRANTS AND ASSISTANCE |
2023 |
2022 |
|||||||
NRC-IRAP |
$ | $ | ||||||
BioTalent Canada |
||||||||
Total |
$ |
$ |
||||||
16. |
INCOME TAXES |
Year ended December 31, |
2023 |
2022 |
||||||
Canadian |
$ | ( |
) | $ | ( |
) | ||
Foreign |
( |
) | ( |
) | ||||
Total |
$ |
( |
) |
$ |
( |
) | ||
Year ended December 31, |
2023 |
2022 |
||||||
Canadian |
||||||||
Current |
$ |
$ |
||||||
Deferred |
$ |
$ |
||||||
$ |
$ |
|||||||
Foreign |
||||||||
Current |
$ |
$ |
||||||
Deferred |
$ |
$ |
||||||
$ |
$ |
|||||||
Total |
||||||||
Current |
$ |
$ |
||||||
Deferred |
$ |
$ |
||||||
$ |
$ |
|||||||
16. |
INCOME TAXES (continued) |
Year ended December 31, |
2023 |
2022 |
||||||
Loss before taxes |
$ | ( |
) | $ | ( |
) | ||
Statutory Canadian corporate tax rate |
% | % | ||||||
Expected tax recovery at statutory rates |
( |
) |
( |
) | ||||
Change in unrecognized deferred tax assets |
||||||||
Non-deductible share-based payments |
||||||||
Other items not deductible for tax purposes and other |
||||||||
Adjustments related to prior years |
( |
) | ( |
) | ||||
Share issue costs |
( |
) | ( |
) | ||||
Foreign exchange arising on translation to reporting currency |
( |
) | ||||||
Income tax expense |
$ |
$ |
||||||
December 31, 2023 |
December 31, 2022 |
|||||||
Convertible debt |
$ | $ | ||||||
Depreciable assets |
||||||||
Lease obligation |
||||||||
Non-capital losses |
||||||||
Share issue costs |
||||||||
Scientific research and experimental development pool |
||||||||
Tax credits |
||||||||
Other |
||||||||
Less: valuation allowance |
( |
) |
( |
) | ||||
Net deferred income tax assets |
$ |
$ |
||||||
16. |
INCOME TAXES (continued) |
Expiry date |
Non-capital losses– Canada |
Non-capital losses– US |
Non-capital losses– Australia |
|||||||||
2031 |
$ | $ | $ | |||||||||
2032 |
||||||||||||
2033 |
||||||||||||
2034 |
||||||||||||
2035 |
||||||||||||
2036 |
||||||||||||
2 037 |
||||||||||||
2038 |
||||||||||||
2039 |
||||||||||||
2040 |
||||||||||||
2041 |
||||||||||||
2042 |
||||||||||||
2043 |
||||||||||||
Unlimited |
||||||||||||
$ |
$ |
$ |
||||||||||
17. |
COMMITMENTS |
18. |
FINANCIAL INSTRUMENTS |
18. |
FINANCIAL INSTRUMENTS (continued) |
18. |
FINANCIAL INSTRUMENTS (continued) |
Financial assets/liabilities |
December 31, 2023 |
December 31, 2022 |
||||||
Cash and cash equivalents |
$ | $ | ||||||
Amounts receivable |
$ | $ | ||||||
Accounts payable and accrued liabilities |
$ | $ | ||||||
Payable to Auritec |
$ | $ | ||||||
Loans payable |
$ | $ |
18. |
FINANCIAL INSTRUMENTS (continued) |
Convertible Debt |
||||
Balance – December 31, 2021 |
$ |
|||
Accrued interest |
||||
Interest paid |
( |
) | ||
Change in fair value |
||||
Foreign exchange |
( |
) | ||
Balance - December 31, 2022 |
$ |
|||
Accrued interest |
||||
Interest paid |
( |
) | ||
Change in fair value |
||||
Foreign exchange |
||||
Balance - December 31, 2023 |
$ |
|||
19. |
INTEREST EXPENSE |
Year ended December 31, 2023 |
Year ended December 31, 2022 |
|||||||
Interest on SVB debt facility (Note 11) |
$ | $ | ||||||
Other interest and accretion |
||||||||
|
|
|
|
|||||
Total |
$ |
$ |
||||||
|
|
|
|
20. |
SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS |
• | 12 (b)(v)). |
• | 12 (b)(i)). |
December 31, 2023 |
December 31, 2022 |
|||||||
Cash |
$ | $ | ||||||
Cash equivalents |
||||||||
|
|
|
|
|||||
Total |
$ |
$ |
||||||
|
|
|
|
21. |
SUBSEQUENT EVENT |